HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)

NCT07105748 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Mixed Hepatocellular-cholangiocarcinoma

Interventions

DRUG: Camrelizumab
DRUG: Rivoceranib (Apatinib)
PROCEDURE: HAIC

Sponsor

Fudan University